Ind-Swift Laboratories
+50.15% revenue YoY
Q2 FY2027 · Period ended 30 Sep 2026
Basis: Standalone only, unaudited
Reported revenue (₹ crore, except EPS in ₹/share): 234.89
Read summary and comparison caveats
On a standalone basis, Ind-Swift Laboratories reported revenue of ₹234.89 crore, up 50.15% year on year and 26.23% sequentially. Reported net profit was ₹31.03 crore, compared with ₹8.76 crore a year ago and ₹24.44 crore in June. These are parent-company figures, not consolidated group profit. Interim PAT excludes any deferred-tax adjustment, which the filing says will be provided at year end.
- Source: standalone statement on PDF page 4 and notes on pages 13-14. Original ₹ lakh amounts are divided by 100 for crore; changes use original figures before display rounding. EPS is reported and not annualised.
- Year ago is the quarter ended 30 Sep 2025; previous quarter is 30 Jun 2026. Standalone coverage is deliberate: the separate consolidated table is not mixed with this statement, and no owners-attributable group PAT is inferred.
- The company says no deferred-tax adjustment has been made under Ind AS 12 because it will be provided at year end. This is a material basis limitation on the reported interim PAT; no normalised tax or adjusted PAT is estimated.
- Exceptional expense of ₹0.58 crore relates to balances written back/written off on amounts no longer payable/receivable; it was ₹0.24 crore in June and nil a year ago. Reported PAT retains those items.
- Reported standalone basic EPS is ₹3.57 versus ₹1.09 a year ago and ₹2.81 in June; diluted EPS is ₹3.56 versus ₹1.05 and ₹2.81. No per-share figures are inferred from closing capital.
- Selected checked coverage from the original filing. Raw RSS notice time has no timezone suffix.
Checked 29 Oct 2026
Open original filing